Table 6.

Recombinant factor VIIa (rFVIIa) utilization.

Series2002 Jan–June2002 July–Dec2003 Jan–June2003 July–Dec2004 Jan–JuneTotal
* Values expressed as means ± SD with range in parenthesis. 
All patients (n) 5 14 26 47 38 130 
# of doses 18 45 121 121 78 383 
Mean total dose*
 (mg) (range) 12.2 ± 9.1
 (2.4–24) 12.0 ± 12.1 
 (2.4–48) 21.2 ± 50.5 
 (2.4–246) 10.4 ± 13.0 
 (1.2–60) 8.6 ± 13.5 
 (1.2–84) 12.5 ± 26.0
 (1.2–246) 
On-label – FVIII Inhibitors (n) 2 0 2 2 2 8 
# of doses 9 0 79 12 26 126 
Mean total dose*
 (mg) (range) 14.4 ± 6.8 
 (9.6–19.2) - 125 ± 121 
 (4–246) 57 ± 2.5 
 (55.2–58.8) 43.2 ± 57.7 
 (2.4–84.0) 75.7 ± 80.8
 (2.4–246) 
Off-label (n) 3 14 24 45 36 122 
# of doses 9 45 42 100 52 248 
Mean total dose* 
 (mg) (range) 10.8 ± 11.6 
 (2.4–24) 12 ± 12.1 
 (2.4–48) 8.2 ± 4.8 
 (2.4–24.5) 8.3 ± 8.6 
 (1.2–60) 6.7 ± 5.2 
 (1.2–27.6) 8.3 ± 7.7
 (1.2–60) 
Series2002 Jan–June2002 July–Dec2003 Jan–June2003 July–Dec2004 Jan–JuneTotal
* Values expressed as means ± SD with range in parenthesis. 
All patients (n) 5 14 26 47 38 130 
# of doses 18 45 121 121 78 383 
Mean total dose*
 (mg) (range) 12.2 ± 9.1
 (2.4–24) 12.0 ± 12.1 
 (2.4–48) 21.2 ± 50.5 
 (2.4–246) 10.4 ± 13.0 
 (1.2–60) 8.6 ± 13.5 
 (1.2–84) 12.5 ± 26.0
 (1.2–246) 
On-label – FVIII Inhibitors (n) 2 0 2 2 2 8 
# of doses 9 0 79 12 26 126 
Mean total dose*
 (mg) (range) 14.4 ± 6.8 
 (9.6–19.2) - 125 ± 121 
 (4–246) 57 ± 2.5 
 (55.2–58.8) 43.2 ± 57.7 
 (2.4–84.0) 75.7 ± 80.8
 (2.4–246) 
Off-label (n) 3 14 24 45 36 122 
# of doses 9 45 42 100 52 248 
Mean total dose* 
 (mg) (range) 10.8 ± 11.6 
 (2.4–24) 12 ± 12.1 
 (2.4–48) 8.2 ± 4.8 
 (2.4–24.5) 8.3 ± 8.6 
 (1.2–60) 6.7 ± 5.2 
 (1.2–27.6) 8.3 ± 7.7
 (1.2–60) 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal